Böserjunge & Zocker Forum: Community User: Böserjunge
LEXINGTON, Mass., Sept. 29, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, announced today that the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, is providing an additional $3.7 million in funding for the multiple-year cost-share contract between BARDA and T2 Biosystems. The total potential BARDA funding if all contract options are exercised is $62.0 million, reflecting a reduction in the scope of work under contract option 3. The additional funding will be used to advance the U.S. clinical trials for the T2Resistance® Panel and T2Biothreat® Panel and file submissions to the U.S. Food and Drug Administration (FDA) for U.S. regulatory clearance.
Mehr zu diesem Wert
|
|
Thema | ||
|---|---|---|---|
| 1 | Böserjunge & Zocker | ||
| 2 | T2 Biosystems |
|
|
Thema | ||
|---|---|---|---|
| 1 | DAX Prognose / Germany 40 | -1,02 % | |
| 2 | Aktuelles zu Almonty Industries | -9,90 % | |
| 3 | VONOVIA Hauptdiskussion | +2,13 % | |
| 4 | MICRON TECHNOLOGY Hauptdiskussion | +3,62 % | |
| 5 | FREYR BATTERY | ±0,00 % | |
| 6 | YANDEX Hauptdiskussion | -0,07 % | |
| 7 | Quantum Emotion, redefrei | -2,88 % | |
| 8 | NVIDIA Hauptdiskussion | +1,80 % | |
| 9 | Quantum Crypto Security | -6,64 % | |
| 10 | APLD - 2024 | +8,44 % | Alle Diskussionen |
|
|
Thema | ||
|---|---|---|---|
| 1 | Aktuelles zu Almonty Industries | -9,11 % | |
| 2 | VONOVIA Hauptdiskussion | -1,18 % | |
| 3 | MICRON TECHNOLOGY Hauptdiskussion | +3,38 % | |
| 4 | FREYR BATTERY | ±0,00 % | |
| 5 | YANDEX Hauptdiskussion | -0,23 % | |
| 6 | Quantum Emotion, redefrei | -3,02 % | |
| 7 | NVIDIA Hauptdiskussion | +1,76 % | |
| 8 | APLD - 2024 | +8,44 % | |
| 9 | Quantum Crypto Security | -6,64 % | |
| 10 | Ulis leckere Gerresheimer Trüffel | +7,57 % | Alle Diskussionen |